Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:CRDF NASDAQ:MEIP OTC:ZOMDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$8.73-4.1%$7.60$4.66▼$9.90$143.35M0.6816,909 shs11,508 shsCRDFCardiff Oncology$2.32+2.7%$3.24$2.09▼$5.64$154.35M1.542.91 million shs1.02 million shsMEIPMEI Pharma$4.97+7.6%$4.06$1.46▼$9.00$160.88M0.37574,221 shs507,341 shsZOMDFZomedica$0.04+2.2%$0.04$0.02▼$0.16$41.06M1.63.95 million shs1.13 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%-6.33%+15.17%+38.79%+872,999,900.00%CRDFCardiff Oncology0.00%-4.92%-41.56%-23.43%-2.93%MEIPMEI Pharma0.00%+1.64%-26.26%+130.63%+58.28%ZOMDFZomedica0.00%+4.49%+6.08%-10.85%-72.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/ACRDFCardiff Oncology1.5522 of 5 stars3.41.00.00.00.61.70.6MEIPMEI Pharma1.096 of 5 stars0.02.00.04.21.80.80.6ZOMDFZomedica0.8232 of 5 stars0.05.00.00.02.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.6756.55% UpsideCRDFCardiff Oncology 2.83Moderate Buy$10.10335.34% UpsideMEIPMEI Pharma 0.00N/AN/AN/AZOMDFZomedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZOMDF, CRDF, MEIP, and BHST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $10.007/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$3.506/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$25.19M5.69N/AN/A$0.08 per share109.13CRDFCardiff Oncology$680K226.98N/AN/A$1.86 per share1.25MEIPMEI Pharma$65.30M2.46$5.99 per share0.83$4.96 per share1.00ZOMDFZomedicaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.91M-$0.70N/AN/AN/A-39.95%-11,357.84%-39.94%N/ACRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%9/18/2025 (Estimated)ZOMDFZomedicaN/A-$0.10N/A∞N/AN/AN/AN/AN/ALatest ZOMDF, CRDF, MEIP, and BHST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025BHSTBioHarvest Sciences-$0.1075-$0.15-$0.0425-$0.24$8.53 million$8.52 million7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/AZOMDFZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.600.36CRDFCardiff OncologyN/A4.424.42MEIPMEI PharmaN/A16.7816.78ZOMDFZomedicaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/ACRDFCardiff Oncology16.29%MEIPMEI Pharma52.38%ZOMDFZomedica8.95%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/ACRDFCardiff Oncology7.70%MEIPMEI Pharma3.12%ZOMDFZomedica5.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.42 millionN/AN/ACRDFCardiff Oncology2066.53 million61.40 millionOptionableMEIPMEI Pharma10032.37 million31.36 millionOptionableZOMDFZomedica50979.95 millionN/AN/AZOMDF, CRDF, MEIP, and BHST HeadlinesRecent News About These CompaniesZomedica Corporation and VerticalVet partner to deliver advanced veterinary technologies to independent practicesAugust 22 at 7:08 AM | pharmabiz.comPZomedica Corp. Reports Q2 2025 Financial ResultsAugust 22 at 7:08 AM | msn.comZomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent PracticesAugust 19, 2025 | accessnewswire.comAZomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL(R) Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary MedicineAugust 12, 2025 | accessnewswire.comAZomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support GrowthAugust 6, 2025 | accessnewswire.comAZomedica to Present at the OTCQB Venture Virtual Investor Conference August 7thAugust 5, 2025 | financialpost.comFZomedica to Present at the OTCQB Venture Virtual Investor Conference August 7thAugust 5, 2025 | globenewswire.comZomedica's Fourth Friday at Four Webinar Returns: Spotlight on the Assisi(R) Line - Advancing Drug-Free Healing for PetsJuly 16, 2025 | accessnewswire.comAZomedica Announces Strategic PulseVet(R) Shock Wave Partnership with World Equestrian Center – OcalaJuly 10, 2025 | accessnewswire.comAZomedica Announces Issuance of Additional Patent for its TRUVIEW(R) MicroscopeJune 24, 2025 | accessnewswire.comAZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | finanznachrichten.deZomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform(R) - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | accessnewswire.comAZomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample DilutionMay 21, 2025 | accessnewswire.comAZomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 19, 2025 | accessnewswire.comAZomedica Corp (ZOMDF) Q1 2025 Earnings Call Highlights: Record Revenue Amid Strategic ChallengesMay 16, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comZomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support GrowthMay 15, 2025 | accessnewswire.comAZomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave TherapyMay 13, 2025 | accessnewswire.comAZomedica to Report First Quarter 2025 Financial Results with a Business Update on Thursday, May 15, 2025 at 4:30 pm ETMay 9, 2025 | accessnewswire.comAZomedica CFO Scott Jordan Resigns, Interim Replacement NamedApril 30, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZOMDF, CRDF, MEIP, and BHST Company DescriptionsBioHarvest Sciences NASDAQ:BHST$8.73 -0.37 (-4.07%) As of 08/22/2025 03:54 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Cardiff Oncology NASDAQ:CRDF$2.32 +0.06 (+2.65%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.34 +0.02 (+0.86%) As of 08/22/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.MEI Pharma NASDAQ:MEIP$4.97 +0.35 (+7.58%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.00 +0.03 (+0.50%) As of 08/22/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Zomedica OTC:ZOMDF$0.04 +0.00 (+2.20%) As of 08/22/2025 03:54 PM EasternZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access